Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer’s Treatment
China-based Fosun Pharmaceutical (SHA: 600196) announced that its controlling subsidiary, Fosun Pharma Industrial, has entered...
Boehringer Ingelheim and Re-Vana Partner to Develop First-in-Class Ocular Therapies
German pharmaceutical giant Boehringer Ingelheim (BI) today announced a strategic collaboration and licensing agreement with...
Tigermed Acquires Japan’s Micron CRO to Expand Imaging Expertise in Asia-Pacific
China-based Tigermed (SHE: 300347, HKG: 3347) announced on July 29, 2025, that it has completed...
Eli Lilly’s Mounjaro Approved by China’s NMPA for Type 2 Diabetes Treatment with Insulin
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced that the National Medical Products Administration...
Antengene’s XPOVIO Approved for New Multiple Myeloma Indication by China’s NMPA
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced that the China National Medical Products Administration...
Shanghai Biomedicine M&A Fund Acquires Stake in MicroPort via Share Transfer Agreement
The Shanghai Biomedicine Merger and Acquisition Fund under SIIC Capital has entered into a share...
AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies
UK-based AstraZeneca’s (AZ, NASDAQ: AZN) Biopharmaceuticals Business Unit (BBU), established last year, is undergoing a...
Wuxi Apptec Reports Strong Q2 2025 Results with 20.6% Revenue Growth
China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) announced strong growth in...
BMS and Bain Capital Launch New Autoimmune Disease Focused Biopharma Company
US major Bristol-Myers Squibb (BMS; NYSE: BMY) and Bain Capital announced the formation of a...
BeOne Medicines’ Tislelizumab Receives Positive CHMP Opinion for NSCLC Treatment
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that its PD-1 antibody...
Bristol-Myers Squibb Gains NMPA Approval for Opdivo-Yervoy Combo in NSCLC
US major Bristol-Myers Squibb (BMS; NYSE: BMY) announced that it has received another indication approval...
NMPA Updates 2025 Edition of Medical Narcotic and Psychotropic Substances Catalogs
On July 28, 2025, China’s National Medical Products Administration (NMPA), the Ministry of Public Security,...
Tibet Aim Pharm’s Major Shareholder Transfers Stake to Beijing Fuhao
China-based Tibet Aim Pharm, Inc. (SHE: 002826) announced that its controlling shareholder and actual controller,...
Roche’s Elevidys Receives Negative CHMP Opinion for Duchenne Muscular Dystrophy
Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced today that the Committee for Medicinal...
Aidea Pharma’s Aitribond Approved by Zanzibar Food and Drug Agency
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced that its anti-HIV-1 drug Aitribond has...
Mirxes and NAGAWA Launch Free Gastric Cancer Screening Project in Japan
Singapore-based Mirxes Group (HKG: 2629) announced on July 23, 2025, that it has entered into...
Ascletis Pharma Doses First Patients in U.S. Phase 2a Trial for Monthly GLP-1 Agonist ASC30
China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first participants with obesity or overweight...
Sobi North America’s Doptelet Approved by FDA for Pediatric ITP Treatment
Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi), announced today...
Hengrui and GSK Enter Global Licensing Pact for PDE3/4 Inhibitor HRS-9821
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced on July 28, 2025, that it...
Pfizer and BioNTech’s LP.8.1 COVID-19 Vaccine Gets EMA CHMP Nod
US giant Pfizer Inc., (NYSE: PFE) and Germany-based BioNTech SE (NASDAQ: BNTX) announced today that...